ChemicalBook--->CAS DataBase List--->915810-67-2

915810-67-2

915810-67-2 Structure

915810-67-2 Structure
IdentificationBack Directory
[Name]

Caplacizumab
[CAS]

915810-67-2
[Synonyms]

Caplacizumab
Research Grade Caplacizumab(DHC08501)
Chemical PropertiesBack Directory
[form ]

Liquid
[color ]

Colorless to light yellow
Hazard InformationBack Directory
[Uses]

Caplacizumab (ALX-0681) is a humanized anti-von Willebrand factor (vWF) nanobody. Caplacizumab inhibits the binding of vWF with platelet glycoprotein (GP) Ibα. Caplacizumab inhibits the vWF-mediated platelet adhesion and prevents further microthrombi formation. Caplacizumab can be used for the research of thrombotic thrombocytopenic purpura (TTP)[1][2][3][4].
[in vivo]

Caplacizumab (2.5 mg/kg, s.c., daily, from day 1 to day 5 for preventive group) completely prevents the rapid onset of severe thrombocytopenia and schistocytic hemolytic anemia in a baboon model of acquired thrombotic thrombocytopenic purpura, and promotes the recovery of platelet counts after induction of TTP[3].
Caplacizumab (at plasma levels between 0.3-0.5 μg/mL, i.v. bolus) shows a strong antithrombotic effect in a modified Folts model in baboons[4].
Caplacizumab (5 mg/kg total dose with intravenous and subcutaneous injection; intravenous injection first and subcutaneous injections follow) prevents middle cerebral artery thrombosis in a guinea pig model of middle cerebral artery thrombosis, and reduces brain damage without inducing hemorrhage[5].

Animal Model:Guinea pig (Dunkin-Hartley, male, 350-400 g) model of middle cerebral artery thrombosis[5]
Dosage:5 mg/kg total dose (0.4 mg/kg intravenously + 1.6 mg/kg subcutaneously at time 0 followed by 3 mg/kg subcutaneously 6 h later)
Administration:Intravenous injection first and subcutaneous injections follow
Result:Prevented thrombosis when administered immediately after and 15 min after complete occlusion of the middle cerebral artery.
Reduced brain damage area and did not increase intracerebral hemorrhage.
Reduced microvascular thrombosis in the ischemic brain tissue.
[References]

[1] Ma?lle le Besnerais, et al. Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment. Expert Opin Biol Ther. 2019 Nov;19(11):1127-1134. DOI:10.1080/14712598.2019.1650908
[2] Nakayama M, et al. Effects of caplacizumab, a specific inhibitor of the A1 domain of von Willebrand factor binding with platelet membrane glycoprotein (GP) Ibα, on the length of platelet pseudopods supporting platelet adhesions on immobilized von Willebrand factor under blood flow condition. Journal of Biorheology, 2022, 36(2): 68-75.
[3] Callewaert F, et al. Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood. 2012 Oct 25;120(17):3603-10. DOI:10.1182/blood-2012-04-420943
[4] Ulrichts H, et al. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood. 2011 Jul 21;118(3):757-65. DOI:10.1182/blood-2010-11-317859
[5] Momi S, et al. Reperfusion of cerebral artery thrombosis by the GPIb-VWF blockade with the Nanobody ALX-0081 reduces brain infarct size in guinea pigs. Blood. 2013 Jun 20;121(25):5088-97. DOI:10.1182/blood-2012-11-464545
915810-67-2 suppliers list
Company Name: BOC Sciences  
Tel: 1-631-485-4226; 16314854226
Website: https://www.bocsci.com
Company Name: ShangHai Biochempartner Co.,Ltd  
Tel: 17754423994 17754423994
Website: https://www.biochempartner.com
Company Name: Beijing Solarbio Science & Tecnology Co., Ltd.  
Tel: 010-50973130 17801761073
Website: www.solarbio.com
Company Name: Wuhan Chemstan Biotechnology Co., Ltd.  
Tel: 027-65317797 15926423062
Website: http://www.chemstan.com/
Company Name: Biolab Reagents  
Tel: 18108604356 18108604356
Website: www.biolabreagent.com/
Company Name: Wuhan Jingkangen Biomedical Technology Co., Ltd  
Tel: 13720134139 086-15871494362 13720134139
Website: https://www.jknbiochem.com
Company Name: Shanghai Yifei Biotechnology Co. , Ltd.  
Tel: 021-65675885 18964387627
Website: http://www.efebio.com
Company Name: Shanghai?Medlife?Pharm-Tech?Co.,?Ltd  
Tel: 021-59167510 18117107507
Website: www.med-life.cn/
Company Name: Changsha Fuzhen Biotechnology Co.,LTD  
Tel: 13823398779 13823398779
Website: www.chemicalbook.com/supplier/25777903/
Company Name: Atagenix Laboratories  
Tel: 027-87008169 17762441161
Website: www.abinscience.com/
Company Name: AntibodySystem Laboratories SAS  
Tel: 33175446423
Website: www.antibodysystem.com
Company Name: Biosynth Biological Technology (Suzhou) Co Ltd  
Tel: 51288865780
Website: www.biosynth.com
Company Name: Cell Sciences  
Tel: 9785721070
Website: www.cellsciences.com
Tags:915810-67-2 Related Product Information
220578-59-6 1296818-77-3 680188-33-4 1622140-49-1 676258-98-3 1610010-60-0 1190239-42-9 1826020-80-7 1036734-93-6 2049079-64-1

  • HomePage | Member Companies | Advertising | Contact us | Previous WebSite | MSDS | CAS Index | CAS DataBase | Privacy | Terms | About Us
  • All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.
    According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.
  • Copyright © 2023 ChemicalBook All rights reserved.